ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Trius Therapeutics, Inc. (MM)

Trius Therapeutics, Inc. (MM) (TSRX)

13.64
0.00
(0.00%)
Closed April 26 4:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
13.64
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
13.64
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

TSRX Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.3559
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.58
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.68
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5801
(0.00%)
0
AACGATA Creativity Global
$ 0.8801
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.3559
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.58
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.68
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5801
(0.00%)
0
AACGATA Creativity Global
$ 0.8801
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.3559
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.58
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.68
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5801
(0.00%)
0
AACGATA Creativity Global
$ 0.8801
(0.00%)
0

TSRX Discussion

View Posts
The_Tiller The_Tiller 7 years ago
OK, lesson learned.
👍️0
jamtomorrow2 jamtomorrow2 7 years ago
I didn't think that any shareholders had to opt for the CVRs - that was part of the deal if you accepted the offer from Cubist. I assume you probably sold your shares in the market prior to the offer closing for a small premium to the cash offer.

Anyway for the mighty Merck to sell just $14m of Sivextro in 2016 is pretty amazing. It just shows how much Cubist overpaid for Trius. So we were extremely lucky to get what we got! I have owned 4 biotech shares that sold out for cash plus CVRs. It looks like I'm going to get nothing from any of the CVRs. My view is that I'm a very lucky guy - the shares of all 4 were worth considerably less than the cash that I got.

👍️0
TRUISM TRUISM 7 years ago
Will payment be made under the Trius Contingent Value Rights?

In January 2015, Merck & Co., Inc. (“Merck”) acquired Cubist Pharmaceuticals, Inc. (“Cubist”) which, in 2013, had acquired Trius Therapeutics (“Trius”). The contingent value rights (“CVRs”) received by Trius shareholders as part of the 2013 Trius/Cubist transaction remained an obligation of Cubist, now a wholly- owned Merck subsidiary.

Payments were to be made under those CVRs only if SIVEXTRO (tedizolid phosphate) achieved $125 million in net sales in 2016 in specified territories. Net sales for SIVEXTRO in 2016 were $14 million; therefore payment will not be made under the Trius CVRs.

I didn't opt for the CVR's due to the feeling tedizolid wouldn't be pushed aggressively enough, as to meet the milestone....



Blessings to All

TRUTH
👍️0
jamtomorrow2 jamtomorrow2 7 years ago
Net sales for Sivextro in 2016 were $14 million. Please see the link below for an FAQ on the details.

http://s21.q4cdn.com/488056881/files/doc_downloads/other/Trius-CVR-FAQ-2.2.17-(1).pdf
👍️0
jamtomorrow2 jamtomorrow2 7 years ago
Merck's 2016 results are out but no mention of Sivextro sales. I've written to Merck's investor relations and asked them to let Trius CVR holders know what the sales were. I've not had a reply. Is anyone optimistic that they've achieved over $125m. At the time of the takeover I though the $135m level would easily be achieved but Sivextro barely ever gets mentioned by Merck so now I'm not so sure.
👍️0
The_Tiller The_Tiller 8 years ago
I have some CVR shares. I'm curious about the mechanics of how redemption works- After 2016 sales are tabulated the resulting value in CVR shares are then deposited in our brokerage accounts? At what time in 2017 would this happen?
👍️0
136 136 8 years ago
Alerting OXIS
👍️0
136 136 8 years ago
Check out what is happening over at OXIS . Looking to be an even better play than TSRX was for us.
👍️0
umiak umiak 8 years ago
Thanks T, be well. :)
👍️0
TRUISM TRUISM 8 years ago
Merck Launches New Antibiotic In The UK
Published on 05/06/15 at 11:07am
Click For Link



Merck has launched Sivextro in the UK



Merck has launched the first new drug in a class of antibiotics in the UK in almost 15 years, becoming one of the only big pharma firms to return to this high-priority disease area.

Sivextro (tedizolid phosphate) is the first oral treatment to be released in the oxazolidinone class of antibiotics since 2001. It is approved to treat acute bacterial skin and skin structure infections (ABSSSI).

These infections can often be caused by the MRSA superbug, which is a major factor in the growing problem of antimicrobial resistant (AMR) bacteria.

“AMR is a global problem and the importance of the introduction of new antibacterials, such as Sivextro, cannot be overestimated,” says Professor Jonathan Cooke of the department of medicine, infectious diseases and immunity at Imperial College London.

“New antimicrobial agents and their optimal use through antimicrobial stewardship programmes are key to ensuring patients receive the best treatment for the right condition at the right time, which is in line with the UK AMR Strategy.”

A report commissioned by the UK government has suggested that AMR could kill over 10 million people worldwide a year by 2050 if alternative treatments are not found.

But big pharma firms have been accused of largely been ignoring antibiotics over the past few decades in favour of more profitable treatment areas. A recent Government-backed report called for a $2 billion global fund to be established to incentivise the development of new antibiotics.

Derek Butler, the chair of the charity MRSA Action UK, says: “I hope that this will be the start of things to come. We need pharmaceutical companies, governments, those providing healthcare and the public to all play their part in using these new treatments wisely. However, there is still a way to go to bring about the change in a culture that has relied too heavily on these golden bullets.”

AMR will be a key topic on the agenda of the G7 summit of world leaders, taking place in June in Schloss Elmau, Germany. Last month the UK Government announced £3 million in funding to help support developing countries to tackle AMR, at the same time as the World Health Organisation’s World Health Assembly in Geneva formally adopted a Global Action Plan against antimicrobial resistance.

Sivextro was originally developed by Cubist, which was acquired by Merck in December 2014 in a $9.5 billion deal. Cubist’s goal is to release at least four new antibiotics by 2020, and it hopes that this will double its 2012 global revenues to $2 billion by 2017.

Its biggest-selling drug is the antibiotic Cubicin (daptomycin), which is marketed by Novartis in the EU. Another of its antibiotics, Zerbaxa (ceftolozane/tazobactam), was approved by the FDA last year for urinary tract or intra-abdominal infections caused by certain kinds of bacteria, and is currently under review by the EMA.




Blessings to All

TRUTH
👍️0
TRUISM TRUISM 8 years ago
Merck Gives Cautious 2016 Outlook As Sales Of Top Medicines Lag
BY RANSDELL PERSON Wed Feb 3, 2016 12:56pm EST
Click For Link


A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009.
REUTERS/JEFF ZELEVANSKY



Merck & Co Inc (MRK.N) on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug, sending its shares down nearly 3 percent.

Sales of Januvia and a related drug called Janumet, the company's biggest franchise, fell 12 percent to $1.45 billion. Merck said wholesalers had stocked up in the prior quarter, and the products face growing competition from other oral diabetes treatments.

But Adam Schechter, the company's head of global human health, said Januvia sales should increase this year, excluding the effects of a stronger dollar, which reduces the value of revenue from overseas.

Januvia sales did not suffer after recent data showed Eli Lilly & Co's (LLY.N) rival Jardiance drug sharply reduced deaths among diabetics at risk of heart attack, Schechter said.

Sales of Remicade, which is facing competition outside the United States from cheaper biosimilars, dropped 29 percent to $396 million. In a conference call with analysts, Schechter said the drug's market share was shrinking, and the trend would accelerate.

"Our initial read on the earnings and guidance reaffirms our neutral stance on (Merck) as pressure on key products such as Januvia and Remicade will likely limit near-term growth," Credit Suisse analyst Vamil Divan said.

Merck is counting on Keytruda, a recently approved treatment for melanoma and lung cancer, to boost its earnings for years to come. The medicine, which takes the brakes off the immune system, is competing with Bristol-Myers Squibb Co's (BMY.N) similar Opdivo treatment, which is picking up sales faster.

Keytruda sales rose to $214 million in the fourth quarter, about half Opdivo's $475 million in revenue in that period.

Merck, the second-largest U.S. drugmaker behind Pfizer Inc (PFE.N), forecast full-year earnings of $3.60 to $3.75 per share, excluding special items. The analysts' average estimate was $3.72, according to Thomson Reuters I/B/E/S.

Merck said it expected 2016 revenue of $38.7 billion to $40.2 billion. Wall Street had forecast $40.25 billion.

Fourth-quarter revenue fell 3 percent to $10.22 billion, below analysts' expectations of $10.35 billion. Sales would have risen 4 percent if not for the stronger dollar.

Net income fell to $976 million from $7.32 billion.

Excluding costs from last year's acquisition of Cubist Pharmaceuticals and other special items, earnings of 93 cents per share topped Wall Street's forecast of 91 cents. Analysts largely attributed the profit beat to a lower tax rate.



Blessings to All

TRUTH
👍️0
TRUISM TRUISM 8 years ago
please share the status of the TSRX CVR's. I see CBST was bought by MRK eoy 2014.

Please see:


Possible Impact of Merck Acqusition of Cubist on the Trius CVR-12/8/14



I was just asked about the potential impact on the value of the Trius CVR of the Merck acquisition of Cubist. You may recall that when Trius was acquired, Trius shareholders received $1.00 for each share that they tendered. If Syvestro (tedizolid) sales in the US, Europe and Canada reach $125 million in 2016 we get $1.00 and we get $2.00 if they meet or exceed $135 million.

In between the payment is pro rata for each $1 million of sales so that at $126 million we will get $1.10, at 127 million $1.20 and so on. The CVRs are non-tradable following the acquisition. This feature means that they will be subject to the capital gains rate rather than ordinary income if and when they are paid.

Whatever Trius could have done on its own, there is no question that the already in place robust sales and marketing infrastructures of Cubist will bolster sales. The same could be said in regard to the impact that Merck will have relative to Cubist. Merck has a powerful marketing organization outside of the US while Cubist gets almost all of its sales in the US. Merck also has long experience in hospital infectious disease marketing through marketing the carbipenem antibiotic Primaxin and the anti-fungal agent Cancidas.

My estimate for 2016 sales was $137 million as of my last report on Trius. I have not been following Cubist closely. However, I note that one Wall Street analyst whom I respect recently put out a note with estimates for Syvextro (tedizolid) of $12 million in 2014, $67 million in 2015 and $122 million in 2016. Let’s hope that Merck can nudge Syvextro over the $135 million milestone in 2016. Aaaah, the good old days.




Blessings to All

TRUTH
👍️0
umiak umiak 8 years ago
Hello! Just curious, if you continued to hold, please share the status of the TSRX CVR's. I see CBST was bought by MRK eoy 2014.
👍️0
someconcerns someconcerns 9 years ago
Mille Grazie. I think Smith's estimates from a year ago were higher and don't we get compensated based on 2016?. I posted those below. We shall see.
👍️0
noretreat noretreat 9 years ago
consensus as of a while back was around 35m 2015, 62M 2016, 148m 2018 rising to 300m in 2020.

I have not followed it real closely since it got absorbed into the behemoth that is Merck. the rumor, of course, is that Merck will hold the drug back to avoid the CVR payments...in my view that would be counterproductive. I sold everything out after the Cubist buyout was announced so I hold no CVRs
👍️0
someconcerns someconcerns 9 years ago
NR, Have you heard anything regarding the sales of Tedizolid, which of course determines the value of our CVRs here. TIA, Steve
👍️0
someconcerns someconcerns 9 years ago
Larry Smith posted this on his blog:

" Possible Impact of Merck Acqusition of Cubist on the Trius CVR

Posted by Larry Smith on Dec 8, 2014 • (0)

I was just asked about the potential impact on the value of the Trius CVR of the Merck acquisition of Cubist. You may recall that when Trius was acquired, Trius shareholders received $1.00 for each share that they tendered. If Syvestro (tedizolid) sales in the US, Europe and Canada reach $125 million in 2016 we get $1.00 and we get $2.00 if they meet or exceed $135 million. In between the payment is pro rata for each $1 million of sales so that at $126 million we will get $1.10, at 127 million $1.20 and so on. The CVRs are non-tradable following the acquisition. This feature means that they will be subject to the capital gains rate rather than ordinary income if and when they are paid.

Whatever Trius could have done on its own, there is no question that the already in place robust sales and marketing infrastructures of Cubist will bolster sales. The same could be said in regard to the impact that Merck will have relative to Cubist. Merck has a powerful marketing organization outside of the US while Cubist gets almost all of its sales in the US. Merck also has long experience in hospital infectious disease marketing through marketing the carbipenem antibiotic Primaxin and the anti-fungal agent Cancidas.

My estimate for 2016 sales was $137 million as of my last report on Trius. I have not been following Cubist closely. However, I note that one Wall Street analyst whom I respect recently put out a note with estimates for Syvextro (tedizolid) of $12 million in 2014, $67 million in 2015 and $122 million in 2016. Let’s hope that Merck can nudge Syvextro over the $135 million milestone in 2016. Aaaah, the good old days."

http://smithonstocks.com/possible-impact-of-merck-acqusition-of-cubist-on-the-trius-cvr/
👍️0
gumbygaya gumbygaya 9 years ago
Any idea what happens with the $1.0+ shareholder bonus on achieving sales goal of tetizold TR-701 (supposed to kick in 2017) with Merck acquisition of cubist. Does the timetable accelerate for original shareholders of trius?
👍️0
noretreat noretreat 9 years ago
Thanks...have you been following CTIX? On a run....
👍️0
136 136 9 years ago
Hey bud it's been a while. But I found another GOOD one.

PXYN , big move coming by / on friday due to earnings.

Look into it if you have the time

👍️0
136 136 10 years ago
Could easily be one. I hope it just moves up though. No gap would be preferred! But these mid .002's are going to go fast. .003's will be up today pretty quick. We hit .0028 Friday on decent volume and there was no resistance. Closed over the support of MA 50 @ .0021
👍️0
noretreat noretreat 10 years ago
elay. watching closely. looks like a gap up
👍️0
noretreat noretreat 10 years ago

👍️0
noretreat noretreat 10 years ago
Once they get going and get noticed, one of the big guys will steal their tech and price them out of biz. There may be a good run in there first, but the stock is up like 200x already!

I've got in at .07 w/50k on your reco. (thanks), don't know if I'll pull the trigger on 250K more...but I might. Waffling...see a couple of alarm bells.
👍️0
136 136 10 years ago
I am 110% on $NTEK. It is the realest of the real in all of pennyland. It WILL be on a higher exchange early/mid 2014. Cash flow is going to be insane this Q4 13 report. They are very close to releasing information on the manufacture(s) of the Nuvola. Also going to be releasing the RETAIL stores we will be able to drive to and buy one. It's going to be huge. Plus they are a team of decorated silicon valley professionals. Many members of the $NTEK team have extensive experience in the industry and have proven themselves by taking prior start-ups to profitability and making successful companies even better. A team of innovators and visionaries. Plus, we have Seiki and ciao.

Its going to $'s a share very very soon.

This company also has a sweet habit of beating every projection they make. Just a few months ago they projected sales of 100,000 units. (Nuvolas) at $299.00 a pop you're looking at NTEK clocking a $30 MILLION quarter. That my friend is a company that does not belong on the pink sheets. It will justify a market cap of $250 Million-$1 Billion if we can make 30mil in one Quarter.

catch ma' drift?
👍️0
noretreat noretreat 10 years ago
Yeah, I would be standing pat with what I have except for the $ from Trius and also CLDX. Went out and spent some of it but haven't found a home for the bulk of it yet. How sure are you about NTEK? What about the guy named BIG? He seems like quite a character.
👍️0
136 136 10 years ago
Looks like a really good time to get some. But I'm 100% invested right now and I'm not near ready to sell anything. But I will check into it for you and add it to the ol' watchlist
👍️0
noretreat noretreat 10 years ago
Let me know what your pharmacist says. I have a pretty big position since 40cents, have traded down cost to near zero and recently have been adding again to hold until catalysts by mid 2014.
👍️0
noretreat noretreat 10 years ago
I agree about Trius...gonna increase my tax bill! Look into CTIX. RIght now is a pretty good time to enter. 3 IND's coming and a partner. High potential cancer drug and decent potential psoriasis drug, plus partner ready phase 2b antibiotic.
👍️0
136 136 10 years ago
I miss the days when we'd be screaming that a buyout was imminent here. And then, one day, it came to be reality :)

Made some good $$$ here

thanks $TSRX
👍️0
noretreat noretreat 10 years ago
sold nt?k yesterday for .172. too many questions unanswered, in my view. but thanks much for the tip as it was over 2x for me. Best of luck and I will return the favor when I can.
👍️0
LongRun8 LongRun8 11 years ago
My second account was updated late last night to show that the shares in that retirement acct were also paid out. Good timing b/c now I can buy some more stocks in the down market.
👍️0
north40000 north40000 11 years ago
My TSRX shares replaced by cash in non-IRA account on 10-09 also.
👍️0
LongRun8 LongRun8 11 years ago
Just noticed at end of day that my shares in my personal brokerage account got paid out; and now the CVRs are there, too.

The shares in my retirement account have not yet been paid out, but maybe those are coming soon, though.

None of my shares were tendered, so it sounds like those who tendered their shares got paid a lot quicker, which makes sense.

Too bad about your short-term vs. long-term capital gains. To have missed it by that little amount of time is annoying to say the least.

I'm with you, BTW, definitely taking advantage of the down market right now to get more of my fave biotechs. I'll look into the ones you mentioned. After TSRX, my largest holdings are NVAX, PSDV, ARRY, SRPT, and SSH.
👍️0
Rob_ Rob_ 11 years ago
I tendered all my shares in my Wells Fargo ROTH IRA and was paid out on 9/17/13. The CVR's are in my ROTH account listed as Trius Therapeutics Inc. but not associated with a ticker symbol.

I did not tender my shares in my Wells Fargo taxable account and it looks like I just got bought out today (10/9/13) and the CVR's are in my account.

I was hoping to avoid short term capital gains on at least some of my shares but just missed on shares I bought Oct. 12th and 16th of 2012. Had more shares purchased in Nov, Dec, Jan, etc but was at least hoping to get my October shares to long term gains. However, it is bitter sweet as maybe I can pick up some seriously depressed biotechs to replace my TSRX.

I will be buying more CTIX, NNVC, and PVCT.
👍️0
LongRun8 LongRun8 11 years ago
I'm in the same boat as you...didn't tender...didn't get paid yet.
I am wondering if the people who tendered their shares are getting paid yet. I contacted one of my brokers and they said it should start getting paid out Oct 2, so I was hoping that now, a week later, I would have gotten mine. I'm assuming people who tendered are getting preference and getting theirs paid out first, but I wish the whole thing would happen quicker. I want to use those funds for other biotechs, which are taking a nosedive right now.
👍️0
north40000 north40000 11 years ago
2nd question--- no is answer here.
👍️0
LongRun8 LongRun8 11 years ago
Has anybody who tendered their shares seen their shares paid out yet?

Also, has anybody who DIDN'T tender their shares seen their shares paid out yet?

TIA.
👍️0
kris_kade kris_kade 11 years ago
I was referring all the lawsuits that will be thrown out. With regard to money, I assume you just sold for 20 cents more than $13.50 ? For 20 cents you missed getting 1 CVR worth $2 long term.
👍️0
Dynomite4016 Dynomite4016 11 years ago
What happened? I got out of the stock a few days ago and got my money . . . but I'm not understanding what happened - what you mean by your posit
👍️0
kris_kade kris_kade 11 years ago
The goose is finally cooked Shares will be de-listed tomorrow and longs can start counting the bills..lol

FWIW, I already tendered my shares few days ago and expect credit on 18th.

Please turn those lights off, whoever is the last person on the way out..
👍️0
TRUISM TRUISM 11 years ago
On September 4, 2013, the Court of Chancery for the State of Delaware granted the requested consolidation of the Delaware Actions.”

SEC FILING

SEC Filing sent to email address via Trius mailing list approximately an hour ago.


Take Care and God Bless....God Bless Us All.


Truth4Once
👍️0
~ NT ~ ~ NT ~ 11 years ago
It sure was. Should be a good LT bet from here on.
👍️0
TRUISM TRUISM 11 years ago
ITEM 11. ADDITIONAL INFORMATION (Filed September 3,2013 by TRIUS in SEC Document)

CLICK HERE FOR TRIUS SEC FILING

The Offer to Purchase and Item 11 of the Schedule TO, to the extent such Item incorporates by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

The first paragraph under the heading entitled “Securityholder Litigation” of Section 15 of the Offer to Purchase is amended and restated in its entirety as follows:

“ On August 1, 2013, a lawsuit was filed in the Superior Court of California, County of San Diego against Trius, and each member of Trius’ board of directors, Cubist and us. The action was brought by Michael Bemis, who claims to be a stockholder of Trius, on his own behalf, and seeks certification as a class action on behalf of all of Trius’ stockholders. The complaint alleges that the defendants breached their fiduciary duties, and/or aided and abetted the breach of fiduciary duties, owed to Trius’ stockholders in connection with the Offer and the Merger. The complaint seeks injunctive relief enjoining the Offer and the Merger, or, in the event the Offer or the Merger has been consummated prior to the court’s entry of final judgment, rescinding the Offer and the Merger. The complaint also seeks an accounting for all damages and an award of costs, including a reasonable allowance for attorneys’ and experts’ fees and expenses. On August 28, 2013, plaintiff Bemis filed an amended complaint, which includes additional allegations about a purportedly flawed sales process and supposed conflicts of interest, and new allegations that the Solicitation/Recommendation Statement on Schedule 14D-9 omits certain material information.”


Take Care and God Bless....God Bless Us All.


Truth4Once
👍️0
TRUISM TRUISM 11 years ago
Hart-Scott-Rodino Premerger Notification Program

Introductory Guide I
What is the Premerger
Notification Program? An Overview
Revised March 2009
ftc.gov/bc/hsr FTC Premerger Notification Office (202) 326-3100

AN OVERVIEW
Guide I is the first in a series of guides prepared by the Federal Trade Commission’s Premerger Notification Office (“PNO”). It is intended to provide a general overview of the Premerger Notification Program (the “Program”) and to help the reader in determining which types of business transactions are reportable under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, 15 U.S.C. § 18a (§ 7A of the Clayton Act or “the Act”). Guide I describes the basic reportability requirements and how the program works. It also provides a list of alternative information sources to assist you in deciding whether or not you need to file. This Guide will introduce you to certain terminology and concepts regarding the Act and the Premerger Notification Rules (the “Rules”), 16 C.F.R. Parts 801, 802 and 803. Additional information can be obtained on the Federal Trade Commission’s website at http://www.ftc.gov/bc/hsr.
Other Guides in this series provide more detailed information. Guide II explains in greater detail certain terms used in the Act and the Rules, and analyzes a hypothetical transaction to determine whether it is reportable and Guide III contains “A Model Request for Additional Information and Documentary Material (Second Request).”
The Guides are not intended to address specific proposed transactions. If you are analyzing a transaction, we suggest that you not only consult the Act, the Rules, and the other Guides in this series, but also the additional material referenced in Section XII of this Guide. If you have specific questions not addressed in these reference sources, call the PNO between the hours of 8:30AM and 5:00PM, Monday through Friday, except holidays, at (202) 326-3100.

I. INTRODUCTION
The Act requires that parties to certain mergers or acquisitions notify the Federal Trade Commission and the Department of Justice (the “enforcement agencies”) before consummating the proposed acquisition. The parties must wait a specific period of time while the enforcement agencies review the proposed transaction. The Program became effective September 5, 1978, after final promulgation of the Rules.1
The Program was established to avoid some of the difficulties and expense that the enforcement agencies encounter when they challenge anticompetitive acquisitions after they have occurred. In the past, the enforcement agencies found that it is often impossible to restore competition fully once a merger takes place. Furthermore, any attempt to reestablish competition after the fact is usually very costly for the parties and the public. Prior review under the Program enables the Federal Trade Commission (“FTC” or the “Commission”) and the Department of Justice (“DOJ”) to determine which acquisitions are likely to be anticompetitive and to challenge them at a time when remedial action is most effective.
In general, the Act requires that certain proposed acquisitions of voting securities, non-corporate interests (“NCI”) or assets be reported to the FTC and the DOJ prior to consummation. The parties must then wait a specified period, usually 30 days (15 days in the case of a cash tender offer or a bankruptcy sale), before they may complete the transaction. Much of the information needed for a preliminary antitrust evaluation is included in the notification filed with the agencies by the parties to proposed transactions and thus is immediately available for review during the waiting period.
Whether a particular acquisition is subject to these requirements depends upon the value of the acquisition and the size of the parties, as measured by their sales and assets. Small acquisitions, acquisitions involving small parties and other classes of acquisitions that are less likely to raise antitrust concerns are excluded from the Act’s coverage.
If either agency determines during the waiting period that further inquiry is necessary, it is authorized by Section 7A(e) of the Clayton Act to request additional information or documentary materials from the parties to a reported transaction (a “second request”). A second request extends the waiting period for a specified period, usually 30 days (ten days in the case of a cash tender offer or a bankruptcy sale), after all parties have complied with the request (or, in the case of a tender offer or a bankruptcy sale, after the acquiring person complies). This additional time provides the reviewing agency with the opportunity to analyze the submitted information and to take appropriate action before the transaction is consummated. If the reviewing agency believes that a proposed transaction may violate the antitrust laws, it may seek an injunction in federal district court to prohibit consummation of the transaction.
1 The Premerger Notification Rules are found at 16 C.F.R. Parts 801, 802 and 803. The Rules also are identified by number, and each Rule beginning with Rule 801.1 corresponds directly with the section number in the C.F.R. (so that Rule 801.40 would be found in 16 C.F.R. § 801.40). In this Guide, the Rules are cited by Rule number.
Page 1 of 16
The Program has been a success. Compliance with the Act’s notification requirements has been excellent, and has minimized the number of post-merger challenges the enforcement agencies have had to pursue. In addition, although the agencies retain the power to challenge mergers post-consummation, and will do so under appropriate circumstances, the fact that they rarely do has led many members of the private bar to view the Program as a helpful tool in advising their clients about particular acquisition proposals.
The Rules, which govern compliance with the Program, are necessarily technical and complex. We have prepared Guide I to introduce some of the Program’s specially defined terms and concepts. This should assist you in determining if proposed business transactions are subject to the requirements of the Program.
II. DETERMINING REPORTABILITY
The Act requires persons contemplating proposed business transactions that satisfy certain size criteria to report their intentions to the enforcement agencies before consummating the transaction. If the proposed transaction is reportable, then both the acquiring person and the person whose business is being acquired must submit information about their respective business operations to the enforcement agencies and wait a specific period of time before consummating the proposed transaction. During that waiting period, the enforcement agencies review the antitrust implications of the proposed transaction. Whether a particular transaction is reportable is determined by application of the Act, the Rules, and formal and informal staff interpretations.
As a general matter, the Act and the Rules require both acquiring and acquired persons to file notifications under the Program if all of the following conditions are met:
2
1. As a result of the transaction, the acquiring person will hold an aggregate amount of voting securities, NCI and/or assets of the acquired person valued in excess of $200 million (as adjusted)2, regardless of the sales or assets of the acquiring and acquired persons3; or
2. As a result of the transaction, the acquiring person will hold an aggregate amount of voting securities, NCI and/or assets of the acquired person valued in excess of $50 million (as adjusted) but at $200 million (as adjusted) or less; and
The 2000 amendments to the Act require the Commission to revise certain thresholds annually based on the change in the level of gross national product. A parenthetical “(as adjusted)” has been added where necessary throughout the Rules (and in this guide) to indicate where such a change in statutory threshold value occurs. The term “as adjusted” is defined in subsection 801.1 (n) of the Rules and refers to a table of the adjusted values published in the Federal Register notice titled “Revised Jurisdictional Thresholds for Section 7A of the Clayton Act.” The notice contains a table showing adjusted values for the rules and is published in January of each year.
3 See § 7A(a)(2) of the Act.
Page 2 of 16
3. 4. A.
One person has sales or assets of at least $100 million (as adjusted); and The other person has sales or assets of at least $10 million (as adjusted). Size of Transaction Test
The first step is to determine what voting securities, NCI, assets, or combination thereof are being transferred in the proposed transaction. Then you must determine the value of the voting securities, NCI, and/or assets as well as the percentage of voting securities and NCI that will be “held as a result of the acquisition.” Calculating what will be held as a result of the acquisition (referred to as the “size of the transaction”) is complicated and requires the application of several rules, including Rules 801.10, 801.12, 801.13, 801.14 and 801.15. Generally, the securities and/or NCI held as a result of the transaction include those that will be acquired in the proposed transaction, as well as any voting securities and/or NCI of the acquired person, or entities within the acquired person, that the acquiring person already holds. Assets held as a result of the acquisition include those that will be acquired in the proposed transaction as well as certain assets of the acquired person that the acquiring person has purchased within the time limits outlined in Rule 801.13.4
If the value of the voting securities, NCI, assets or combination thereof exceeds $200 million (as adjusted) and no exemption applies, the parties must file notification and observe the waiting period before closing the transaction.
If the value of the voting securities, NCI, assets or combination thereof exceeds $50 million (as adjusted) but is $200 million (as adjusted) or less, the parties must look to the size of person test.
B. Acquiring and Acquired Persons/Acquired Entity
The first step in determining the size of person is to identify the “acquiring person” and “acquired person.” “Person” is defined in Rules 801.1(a)(1) and is the “ultimate parent entity” or “UPE” of the buyer or seller. That is, it is the entity that ultimately controls the buyer or seller.5 The “acquired entity” is the specific entity whose assets, NCI or voting securities are being acquired. The acquired entity may also be its own UPE or it may be an entity within the acquired person.
Thus, in an asset acquisition, the acquiring person is the UPE of the buyer, and the acquired person is the UPE of the seller. The acquired entity is the entity whose assets are being acquired. In a voting securities acquisition, the acquiring person is the UPE of the buyer, the acquired person is the UPE of the entity whose securities are being bought, and the acquired entity is the
4 The Rules on when to aggregate the value of previously acquired voting securities and assets with the value of the proposed acquisition are discussed in greater detail in Guide II.
5 See “control” under 801.1(b).
Page 3 of 16
issuer of the securities being purchased. In an acquisition of NCI, the acquiring person is the UPE of the buyer, the acquired person is the UPE of the entity whose NCI are being bought, and the acquired entity is the entity whose NCI are being acquired. Oftentimes the acquired person and acquired entity are the same.
In many voting securities acquisitions, the acquiring person proposes to buy voting securities from minority shareholders of the acquired entity, rather than from the entity itself (tender offers are an example of this type of transaction). These transactions are subject to Rule 801.30, which imposes a reporting obligation on the acquiring person and on the acquired person, despite the fact that the acquired person may have no knowledge of the proposed purchase of its outstanding securities.6 For this reason, the Rules also require that a person proposing to acquire voting securities directly from shareholders rather than from the issuer itself serve notice on the issuer of the shares to ensure the acquired person knows about its reporting obligation.7
C. Size of Person Test
Once you have determined who the acquiring and acquired persons are, you must determine whether the size of each person meets the Act’s minimum size criteria. This “size of person” test generally measures a company based on the person’s last regularly prepared annual statement of income and expenses and its last regularly prepared balance sheet.8 The size of a person includes not only the entity that is making the acquisition or whose assets or securities are being acquired, but also the UPE and any other entities the UPE controls.9
If the value of the voting securities, NCI, assets or combination thereof exceeds $50 million (as adjusted) but is $200 million (as adjusted) or less, the size of person test is met, and no exemption applies, the parties must file notification and observe the waiting period before closing the transaction.
D. Notification Thresholds
An acquisition that will result in a buyer holding more than $50 million (as adjusted) worth of the voting securities of another issuer crosses the first of five staggered “notification thresholds.”9 The rules identify four additional thresholds: voting securities valued at $100 million (as adjusted) or greater but less than $500 million (as adjusted); voting securities valued at $500 million (as adjusted) or greater; 25 percent of the voting securities of an issuer, if the 25 percent (or any amount above 25% but less than 50%) is valued at greater than $1 billion (as adjusted);
6 7 8 9
See Rule 801.1; Rule 801.30. See Rule 803.5. See Rule 801.11. See Rule 801.1(a)(1).
Page 4 of 16
and 50 percent of the voting securities of an issuer if valued at greater than $50 million (as adjusted).
The thresholds are designed to act as exemptions to relieve parties of the burden of making another filing every time additional voting shares of the same person are acquired. As such, when notification is filed, the acquiring person is allowed one year from the end of the waiting period to cross the threshold stated in the filing.10 If within that year the person reaches the stated threshold (or any lower threshold), it may continue acquiring voting shares up to the next threshold for five years from the end of the waiting period.11 For example, if you file to acquire $100 million (as adjusted) of the voting securities of Company B and cross that threshold within one year, you would be able to continue to acquire voting securities of Company B for a total of five years without having to file again so long as your total holding of Company B’s voting securities did not exceed either $500 million (as adjusted) or 50 percent, i.e., additional notification thresholds. Once an acquiring person holds 50 percent or more of the voting securities of an issuer, all subsequent acquisitions of securities of that issuer are exempt.12
These notification thresholds apply only to acquisitions of voting securities. The 50 percent threshold is the highest threshold regardless of the corresponding dollar value.
E. Exempt Transactions
In some instances, a transaction may not be reportable even if the size of person and the size of transaction tests have been satisfied. The Act and the Rules set forth a number of exemptions, describing particular transactions or classes of transactions that need not be reported despite meeting the threshold criteria.13 For example, certain acquisitions of assets in the ordinary course of a person’s business are exempted, including new goods and current supplies (e.g., an airline purchases new jets from a manufacturer, or a supermarket purchases its inventory from a wholesale distributor).14 The acquisition of certain types of real property also would not require notification. These include certain new and used facilities, not being acquired with a business, unproductive real property (e.g., raw land), office and residential buildings, hotels (excluding hotel casinos), certain recreational land, agricultural land and retail rental space and warehouses.15 In addition, the acquisition of foreign assets would be exempt where the sales in or
10 See Rule 803.7. 11 See Rule 802.21. 12 See § 7A(c)(3) of the Act, 15 U.S.C. § 18a(c)(3). 13 See § 7A(c) of the Act, 15 U.S.C. § 18a(c), and Part 802 of the Rules, 16 C.F.R. Part 802. 14 See Rules 802.1(b) and 802.1(c). 15 See Rules 802.2(c) - (h).
Page 5 of 16
into the U.S. attributable to those assets were $50 million (as adjusted) or less.16 Once it has been determined that a particular transaction is reportable, each party must submit its notification to the FTC and the DOJ. In addition, each acquiring person must pay a filing fee to the FTC for each transaction that it reports (with a few exceptions, see IV below).
III. THE FORM
The Notification and Report Form (“the Form”) solicits information that the enforcement agencies use to help evaluate the antitrust implications of the proposed transaction. Copies of the Form, Instructions, and Style Sheet are available from the PNO, (202) 326-3100, as well as the FTC website at http://www.ftc.gov/bc/hsr.
A. Information Reported
In general, a filing party is required to identify the persons involved and the structure of the transaction. The reporting person also must provide certain documents such as balance sheets and other financial data, as well as copies of certain documents that have been filed with the Securities and Exchange Commission. In addition, the parties are required to submit certain planning and evaluation documents that pertain to the proposed transaction.
The Form also requires the parties to disclose whether the acquiring person and acquired entity currently derive revenue from businesses that fall within any of the same industry and product North American Industry Classification System (“NAICS”) codes,17 and, if so, in which geographic areas they operate. Identification of overlapping codes may indicate whether the parties engage in similar lines of business. Acquiring persons must also describe certain previous acquisitions in the last five years of companies or assets engaged in businesses in any of the overlapping codes identified. Please note that an acquiring person must complete the Form for all of its operations; an acquired person, on the other hand, must limit its response in Items 5 through 7 to the business or businesses being sold and does not need to answer Item 8.18 In addition, the acquired person does not need to respond to Item 6 in a pure asset transaction.
16 See Rules 802.50 and 802.51.
17 For information concerning NAICS codes see the North American Industry Classification System, 2002, published by the Executive Office of the President, Office of Management and Budget and available from the National Technical Information Service, 5285 Port Royal Road, Springfield VA 22161 (Order Number PB 2002-101430) or online at http://www.ntis.gov/search/product.aspx?ABBR=PB2002101430; and The 2002 Economic Census Numerical List of Manufactured and Mineral Products published by Bureau of the Census, available from the Government Printing Office or online at http://www.census.gov/prod/ec02/02numlist/m31r-nl.pdf. Information regarding NAICS also is available at the Bureau of the Census website at http://www.census.gov/epcd/www/naics.html.
18 See 803.2(b).
Page 6 of 16
B. Contact Person
The parties are required to identify an individual (listed in Item 1(g) of the Form) who is a representative of the reporting person and is familiar with the content of the Form. This contact person is, in most cases, either counsel for the party or an officer of the company. This person must be available during the waiting period.
C. Certification and Affidavits
Rule 803.5 describes the affidavit that must accompany certain Forms. In transactions where the acquiring person is purchasing voting securities from non-controlling shareholders, only the acquiring person must submit an affidavit. The acquiring person must state in the affidavit that it has a good faith intention of completing the proposed transaction and that it has served notice on the acquired person as to its potential reporting obligations.19 In all other transactions, each of the acquired and acquiring persons must submit an affidavit with their Forms, attesting to the fact that a contract, an agreement in principle, or a letter of intent has been executed and that each person has a good faith intention of completing the proposed transaction. These required statements govern when the parties may make a premerger notification filing. The affidavit is intended to assure that the enforcement agencies will not be presented with hypothetical transactions for review.20
Rule 803.6 provides that the Form must be certified and the rule specifies who must make the certification.21 One of the primary purposes of the certification is to preserve the evidentiary value of the filing. It also is intended to place responsibility on an individual to ensure that information reported is true, correct, and complete. Both the certification and the affidavit must be notarized, or may be signed under penalty of perjury.22
19 See Rule 803.5(a)(i)(I) through (vi) for the full requirements of such notice. In tender offers, the acquiring person also must affirm that the intention to make the tender offer has been publicly announced. See Rule 803.5(a)(2).
20 See Statement of Basis and Purpose to Rule 803.5, 43 Fed. Reg. 33510-33511 (1978). 21 The certification may be signed by a general partner of a partnership; an officer or director of a corporation; or, in
the case of a natural person, the natural person or his/her legal representative.
22 28 U.S.C. § 1746 allows use of the following statement in lieu of a notary’s jurat: “I declare (or certify, verify or state) under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed on (date) [and] (Signature).” The italicized text is necessary only if signed outside the territorial United States.
Page 7 of 16
D. Voluntary Information
The rules provide that reporting persons also may submit information that is not required by the Form.23 If persons voluntarily provide information or documentary material that is helpful to the competitive analysis of the proposed transaction, the enforcement agencies’ review of a proposed transaction may be more rapid. However, voluntary submissions do not guarantee a speedy review. Voluntary submissions are included in the confidentiality coverage of the Act and the Rules.
E. Confidentiality
Neither the information submitted nor the fact that a notification has been filed is made public by the agencies except as part of a legal or administrative action to which one of the agencies is a party or in other narrowly defined circumstances permitted by the Act.24 However, in response to inquiries from interested parties who wish to approach the agencies with their views about a transaction, the agencies may confirm which agency is handling the investigation of a publicly announced merger.25 The fact that a transaction is under investigation also may become apparent if the agencies interview third parties during their investigation.
F. Filing Procedures
The parties should complete and return the original and one copy of the Form, along with one set of documentary attachments, to the Premerger Notification Office, Bureau of Competition, Room 303, Federal Trade Commission, 600 Pennsylvania Avenue, NW, Washington, D.C. 20580. Three copies of the Form, along with one set of documentary attachments, should be sent to the Department of Justice, Antitrust Division, Office of Operations, Premerger Notification Unit, 950 Pennsylvania Avenue, NW, Room 3335, Washington, DC 20530 (for non-USPS deliveries, use zip code 20004).
IV. THE FILING FEE
In connection with the filing of a Form, Congress also mandated the collection of a fee from each acquiring person. The filing fee is based on a three-tiered system that ties the amount paid to the total value of the voting securities, NCI or assets held as a result of the acquisition:26
23
24
See Rule 803.1(b). See Section 7A(h) of the Act. A publicly announced merger is one in which a party to the merger has disclosed the existence of the transaction
25 in a press release or in a public filing with a governmental body.
26 The filing fee thresholds are adjusted annually for changes in the GNP during the previous year. The fees themselves are not adjusted.
Page 8 of 16
VALUE OF VOTING SECURITIES, NCI OR ASSETS TO BE HELD
FEE AMOUNT
greater than $50 million (as adjusted) but less than $100 million (as adjusted)
$45,000
$100 million (as adjusted) or greater but less than $500 million (as adjusted)
$125,000
$500 million (as adjusted) or greater
$280,000
For transactions in which more than one person is deemed to be the acquiring person, each acquiring person must pay the appropriate fee (except in consolidations and in transactions in which there are two acquiring persons that would have exactly the same responses to Item 5 of the Form).27 In addition, an acquiring person will have to pay multiple filing fees if a series of acquisitions are separately reported.28
The filing fee must be paid at the time of filing to “The Federal Trade Commission” by electronic wire transfer, bank cashier’s check or certified check. Rule 803.9 contains specific instructions for payment of the filing fee. In addition, information is available at http://www.ftc.gov/bc/hsr/filing2.htm.
V. THE WAITING PERIOD
After filing, the filing parties must then observe a statutory waiting period during which they may not consummate the transaction. The waiting period is 15 days for reportable acquisitions by means of a cash tender offer, as well as acquisitions subject to certain federal bankruptcy provisions, and 30 days for all other types of reportable transactions.29 The waiting period may be extended by issuance of a request for additional information and documentary material.30 Any waiting period that would end on a Saturday, Sunday or legal public holiday will expire on the next regular business day.
A. Beginning of the Waiting Period
In most cases, the waiting period begins after both the acquiring and acquired persons file completed Forms with both agencies. However, for certain transactions in which a person buys
27 For example, if two separate UPEs jointly control an acquisition vehicle and own no other entities, their Item 5 responses would be identical.
28 29 30
See Rule 803.9(a) - (c). See Rule 803.10; 11 U.S.C. § 363(b)(2), as amended (1994). See Section VIII(C), infra.
Page 9 of 16
voting securities from persons other than the issuer (third party and open market transactions), the waiting period begins after the acquiring person files a complete Form. In a reportable joint venture formation, the waiting period begins after all acquiring persons required to file submit complete Forms.31 It is important to note that failure to pay the filing fee or the submission of an incorrect or incomplete filing will delay the start of the waiting period.32
B. Early Termination
Any filing person may request that the waiting period be terminated before the statutory period expires. Such a request for “early termination” will be granted only if (1) at least one of the persons specifies it on the Form; (2) all persons have submitted compliant Forms; and (3) both antitrust agencies have completed their review and determined not to take any enforcement action during the waiting period.33
The PNO is responsible for informing the parties that early termination has been granted. The Act requires that the FTC publish a notice in the Federal Register of each early termination granted. Moreover, grants of early termination also appear on the FTC’s website at http://www.ftc.gov/bc/earlyterm/index.html.
When it’s requested, early termination is granted for most transactions. On the average, requests for early termination are granted within two weeks from the beginning of the waiting period. In any particular transaction, however, the time that it takes to grant a request for early termination depends on many factors, including the complexity of the proposed transaction, its potential competitive impact, and the number of filings from other parties that the enforcement agencies must review at the same time.
VI. REVIEW OF THE FORM
Once a Form has been filed, the enforcement agencies begin their review. The FTC is responsible for the administration of the Program. As a result, the PNO determines whether the Form complies with the Act and the Rules.
The Form is assigned to a member of the PNO staff to assess whether the transaction was subject to the reporting requirements and whether the Form was completed accurately. If the filing appears to be deficient, the staff member will notify the contact person as quickly as possible so that errors can be corrected. It is important to correct the errors as soon as possible because the waiting period does not begin to run until the Form is filled out accurately, all required
31 The joint venture entity does not file. See Rule 802.41. 32 See Rules 803.3 and 803.10(a). 33 See Formal Interpretation 13 issued August 20, 1982.
Page 10 of 16
information and documentary material are supplied and payment of the filing fee is received.34
When the PNO determines that the Forms comply with all filing requirements, letters are sent to the parties identifying the beginning and ending of the waiting period, as well as the transaction number assigned to the filing. The conclusion that the parties have complied with the Act and the Rules may be modified later, however, if circumstances warrant.
VII. ANTITRUST REVIEW OF THE TRANSACTION
Initially, both agencies undertake a preliminary substantive review of the proposed transaction. The agencies analyze the filings to determine whether the acquiring and acquired firms are competitors, or are related in any other way such that a combination of the two firms might adversely affect competition. Staff members rely not only on the information included on the Form but also on publicly available information. The individuals analyzing the Form often have experience either with the markets or the companies involved in the particular transaction. As a result, they may have industry expertise to aid in evaluating the likelihood that a merger may be harmful.
If, after preliminary review, either or both agencies decide that a particular transaction warrants closer examination, the agencies decide between themselves which one will be responsible for the investigation. Only one of the enforcement agencies will conduct an investigation of a proposed transaction. Other than members of the PNO, no one at either agency will initiate contact with any of the persons or any third parties until it has been decided which agency will be responsible for investigating the proposed transaction.35 This clearance procedure is designed to minimize the duplication of effort and the confusion that could result if both agencies contacted individual persons at different times about the same matter. The clearance decision is made pursuant to an agreement that divides the antitrust work between the two agencies.
Of course, any interested person, including either of the parties, is free to present information to either or both agencies at any time. However, if the clearance decision has not yet been resolved, the person must make a presentation, or provide written information or documents, to both agencies. If you are representing a party that wishes to make a presentation, or provide written information or documents, you may inform the PNO of that fact; the PNO will let staff attorneys at both agencies who are reviewing the matter know that persons wish to come in and make a presentation, or provide written information or documents.
34 For transactions in which a person buys voting securities from someone other than the issuer (third party and open market transactions), the waiting period begins after the acquiring person submits a complete and accurate Form. An incorrect or incomplete Form from the acquired person will not stop the running of the waiting period. However, the acquired person still is obligated to correct any deficiencies in its filing.
35 Staff at either agency may initiate contact with a person prior to the resolution of which agency will handle the matter by first notifying the other agency and offering the other agency the opportunity to participate.
Page 11 of 16
VIII. SECOND REQUESTS
Once the investigating agency has clearance to proceed, it may ask any or all persons to the transaction to submit additional information or documentary material to the requesting agency. The request for additional information is commonly referred to as a “second request.”36 As discussed above, although both agencies review each Form submitted to them, only one agency will issue second requests to the parties in a particular transaction.
A. Information Requested
Generally, a second request will solicit information on particular products or services in an attempt to assist the investigative team in examining a variety of legal and economic questions. A typical second request will include interrogatory-type questions as well as requests for the production of documents. A model second request has been produced jointly by the FTC and DOJ for internal use by their attorneys and is contained in Guide III. Because every transaction is unique, however, the model second request should be regarded only as an example.
B. Narrowing the Request
Parties that receive a second request and believe that it is broader than necessary to obtain the information that the enforcement agency needs are encouraged to discuss the possibility of narrowing the request with the staff attorneys reviewing the proposed transaction. Often, the investigative team drafts a second request based only on information contained in the initial filing and other available material. At this point, the investigative team may not have access to specific information about the structure of the company or its products and services. By meeting with staff, representatives of the company have an opportunity to narrow the issues and to limit the required search for documents and other information. If second request modification issues cannot be resolved through discussion with staff, the agencies also have adopted a formal internal appeals process that centralizes in one decision maker in each agency the review of issues relating to the scope of and compliance with second requests.37
The enforcement agency issuing the second request may have determined that certain data sought in the request can resolve one or more issues critical to the investigation. In such a situation, the agency’s staff may suggest use of the informal “quick look” procedure. Under the quick look, the staff will request the parties to first submit documents and other information, which specifically address the critical issues (e.g., product market definition or ease of entry). If the submitted information resolves the staff’s concerns in these areas, the waiting period will be terminated on a sua sponte basis and the parties will not have to expend the time and cost of responding to the full second request. Of course, if the submitted information does not resolve the staff’s concerns on determinative issues, then the parties will need to respond to the full
36 See Rule 803.20(a)(1) for the identities of persons and individuals that are subject to such request. 37 See 66 Fed. Reg. 8721-8722, February 1, 2001.
Page 12 of 16
second request.
C. Extension of the Waiting Period
The issuance of a second request extends the statutory waiting period until 30 days (or in the case of a cash tender offer or certain bankruptcy filings,38 10 days) after both parties are deemed to have complied with the second request (or in the case of a tender offer and bankruptcy, until after the acquiring person has complied).39 During this time, the attorneys investigating the matter may also be interviewing relevant parties and using other forms of compulsory process to obtain information.
The second request must be issued by the enforcement agency before the waiting period expires. If the waiting period expires and the agencies have not issued a second request to any person to the transaction, then the parties are free to consummate the transaction. The fact that the agencies do not issue second requests does not preclude them from initiating an enforcement action at a later time.40 All of the agencies’ other investigative tools are available to them in such investigations.41
IX. AGENCY ACTION
After analyzing all of the information available to them, the investigative staff will make a recommendation to either the Commission or the Assistant Attorney General (depending on which agency has clearance).
A. No Further Action
If the staff finds no reason to believe competition will be reduced substantially in any market, it will recommend no further action. Assuming that the agency concurs in that recommendation, the parties are then free to consummate their transaction upon expiration of the waiting period. As with a decision not to issue a second request, a decision not to seek injunctive relief at that time does not preclude the enforcement agencies from initiating a post-merger enforcement action at a later time.
B. Seeking Injunctive Relief
If the investigative staff believes that the transaction is likely to be anticompetitive, it may recommend that the agency initiate injunction proceedings in U.S. district court to halt the
38 39 40 41
See 11 U.S.C. § 363(b), as amended (1994). See § 7A(e) of the Act. See § 7(A)(i)(1) of the Act. See § 7(A)(i)(2) of the Act.
Page 13 of 16
acquisition. If the Commission or the Assistant Attorney General concurs in the staff’s recommendation, then the agency will file suit in the appropriate district court. If it is a Commission case, the FTC is required to file an administrative complaint within twenty days (or a lesser time if the court so directs) of the granting of its motion for a temporary restraining order or for a preliminary injunction.42 The administrative complaint initiates the FTC’s administrative proceeding that will decide the legality of the transaction. If it is a DOJ case, the legality of the transaction is litigated entirely in district court.
C . Settlements
During an investigation, the investigative staff may, if appropriate, discuss terms of settlement with the parties. The staff of the FTC is permitted to negotiate a proposed settlement with the parties; however, it must then be presented to the Commission, accepted by a majority vote, and placed on the public record for a notice and comment period before it can be made final. A proposed settlement negotiated by DOJ staff must be approved by the Assistant Attorney General and also placed on the public record for a notice and comment period before it will be entered by a district court pursuant to the provisions of the Antitrust Procedures and Penalties Act, 15 U.S.C. § 16(b)-(h).
X. FAILURE TO FILE A. Civil Penalties
If you consummate a reportable transaction without filing the required prior notification or without waiting until the expiration of the statutory waiting period, you may be subject to civil penalties. The Act provides that “any person, or any officer, director or partner thereof” shall be liable for a penalty of up to $16,000 a day for each day the person is in violation of the Act. The enforcement agencies may also obtain other relief to remedy violations of the Act, such as an order requiring the person to divest assets or voting securities acquired in violation of the Act.43
B. Reporting Omissions
If you have completed a transaction in violation of the Act, it is important to bring the matter to the attention of the PNO and to file a notification as soon as possible. Even a late filing provides information to the enforcement agencies that assists them in conducting antitrust screening of transactions and antitrust investigations. The parties should include a letter with the notification from an officer or director of the company explaining why the notification was not filed in a timely manner, how and when the failure was discovered, and what steps have been taken to prevent a violation of the Act in the future. The letter should be addressed to the Deputy Director, Bureau of Competition, Federal Trade Commission, 600 Pennsylvania Ave., NW,
42 FTC Act Section 13(b).
43 See § 7A(g) of the Act, as amended by the Debt Collection Improvements Act of 1996, Pub. L. No. 104134 (Apr. 26, 1996); 61 Fed. Reg. 54548 (Oct. 21, 1996); 61 Fed. Reg. 55840 (Oct. 29, 1996).
Page 14 of 16
Washington DC 20580.
C. Deliberate Avoidance
The Rules specifically provide that structuring a transaction to avoid the Act does not alter notification obligations if the substance of the transaction is reportable.44 For example, the agencies will seek penalties where the parties split a transaction into separate parts that are each valued below the current filing threshold in order to avoid reporting the transaction, but the fair market value of the assets being acquired is actually above the threshold.45
XI. OTHER GUIDES IN THIS SERIES
Guide I is the first in a series of guides prepared by the PNO. Others include:
Guide II: To File Or Not To File -- When You Must File a Premerger Notification Report Form, which explains certain basic requirements of the program and takes you through a step-by-step analysis for determining whether a particular transaction must be reported.
Guide III: A Model Request for Additional Information and Documentary Material (Second Request), which contains materials designed for the attorneys of the antitrust enforcement agencies in preparing requests for additional information. It is included in this series to provide an example of what you might expect if either enforcement agency issues a second request.
XII. OTHER MATERIALS
To make effective use of these guides, you must be aware of their limitations. They are intended to provide only a very general introduction to the Act and Rules and should be used only as a starting point. Because it would be impossible, within the scope of these guides, to explain all of the details and nuances of the premerger requirements, you must not rely on them as a substitute for reading the Act and the Rules themselves. To determine premerger notification requirements, you should consult:
1. Section 7A of the Clayton Act, 15 U.S.C. § 18a, as amended by the Hart- Scott-Rodino Antitrust Improvements Act of 1976, Pub. L. 94-435, 90 Stat. 1390, and amended by Pub. L. No. 106-553, 114 Stat. 2762.
2. The Premerger Notification Rules, 16 C.F.R. Parts 801 – 803. (2008).
3. The Statement of Basis and Purpose for the Rules, 43 Fed. Reg. 33450 (July 31, 1978); 48 Fed. Reg. 34428 (July 29, 1983); 52 Fed. Reg. 7066
44
See Rule 801.90. 45 See, e.g., United States v. Sara Lee Corp., 1996-1 Trade Cas. (CCH) ¶ 71,301 (D.D.C. 1996).
Page 15 of 16
(March 6, 1987); 52 Fed. Reg. 20058 (May 29, 1987); 61 Fed. Reg. 13666 (March 28, 1996); 66 Fed. Reg. 8680 (February 1, 2001); 66 Fed. Reg. 23561 (May 9, 2001); 66 Fed. Reg. 35541 (July 6, 2001); 67 Fed. Reg. 11898 (March 18, 2002); 67 Fed. Reg. 11904 (March 18, 2002); 68 Fed. Reg. 2425 (January 17, 2003); 70 Fed. Reg. 4987 (January 31, 2005); 70 Fed. Reg. 11502 (March 8, 2005); 70 Fed. Reg. 73369 (December 12, 2005); 71 Fed. Reg. 35995 (June 23, 2006).
4. The formal interpretations issued pursuant to the Rules, compiled in 6 Trade Reg. Rep. (CCH) at ¶ 42,475.
It is advisable to check the Federal Register for more recent Rules changes that have not yet been incorporated into the Code of Federal Regulations or these guides. For an up-to-date list of Federal Register notices related to the Statement of Basis and Purpose, see http://www.ftc.gov/bc/hsr/basispurp.shtm. For other HSR-related rulemakings, see http://www.ftc.gov/bc/hsr/rulemaking.shtm. Amendments and formal interpretations, as well as the other material referenced above, are available on the Premerger Notification Office website at http://www.ftc.gov/bc/hsr.
There are also non-governmental publications that, while not officially endorsed by the FTC, contain useful compilations of materials relevant to the Program:
1. Commerce Clearing House’s Trade Regulation Reporter reprints the Act, the Rules, the Form, and the Formal Interpretations.
2. The American Bar Association’s Section of Antitrust Law publishes a Premerger Notification Practice Manual (2007 Edition) that provides a collection of informal interpretations of the PNO.
3. A loose-leaf treatise by Axinn, Fogg, Stoll and Prager, Acquisitions under the Hart-Scott-Rodino Antitrust Improvements Act (published by Law Journal SeminarsPress), explains requirements of the Form, the Rules, and the Act, and includes a discussion of the legislative history of the Act.
Finally, if you have questions about the program or a particular transaction not answered by the Commission’s HSR website, the staff of the PNO is available to assist you. The PNO answers thousands of inquiries each year and is prepared to provide prompt informal advice concerning the potential reportability of a transaction and completion of the Form. For general questions, contact the PNO at (202) 326-3100.

Take Care and God Bless....God Bless Us All.


Truth4Once
👍️0
TRUISM TRUISM 11 years ago
Aug 29, 2013, 11:59am EDT
Cubist announces recall of antibiotic; shares rise regardless

Don Seiffert
Associate Editor MHT-
Boston Business Journal

Cubist Pharmaceuticals Inc. (Nasdaq: CBST) announced a voluntary recall of certain batches of its antibiotic, Cubicin, due to the possibility that they contain particles of glass.
The Lexington, Mass. drug company specified four lots of the drug in an announcement Thursday, all of them for the 500 milligram strength of the injected drug. The lots are: 950453F, with a Dec. 6, 2013 expiration date; 090203F, with a Sept. 7, 2014 expiration date; 201703F, with expiration date of Aug. 31, 2015; and 201653F, with expiration date of Sept. 1, 2015.
Cubicin said there have been no “adverse events” reported.
The company’s stock was up Thursday 2 percent despite the recall, as investor interest in antibiotic companies soars due to international warnings regarding antibacterial resistance, and two pending acquisitions for which Cubist plans to pay as much as $1.62 billion if certain milestones are met. Cubicin’s stock is up 42 percent for the year to date.
=============================================================

Yet and still TSRX PPS stays stagnant,for the most part.

Take Care and God Bless....God Bless Us All.


Truth4Once
👍️0
136 136 11 years ago
Going to be very interesting to see how this all plays out here soon.



$TSRX

It was one hell of a trader's playground.

👍️0
kris_kade kris_kade 11 years ago
Thanks. I also just got the same confirmed after calling Mckanzie Partners who are Information Agent for this merger. I might choose not to tender purely to delay as much as possible the payout, hopefully into 2014 for tax purposes.
👍️0
LongRun8 LongRun8 11 years ago
I know it's a murky situation for sure.

I asked Trius IR about not tendering shares and what would happen. This is what I got back.

Thank you for your inquiry.
If you do not tender your shares and the deal goes through you will receive the $13.50 per share and the CVR.
More information may be found at investor.triusrx.com/sec.cfm


Hillary Theakston
Investor Relations for Trius
htheakston@triusrx.com
(858) 452-0370 x440

So it DOES look like we'll be paid out those shares at the current deal's specifics; which is nice.
👍️0
kris_kade kris_kade 11 years ago
While I am not an expert they are distinguishing the 'offer' from 'merger' with former could be consummated (meaning cash paid) while later may not happen. This is the risk Cubist is taking. If this happens Cubist will be another shareholder of Trius shares and not a parent company.

Also the wording around whether folks who don't tender now are eligible for CVR is not clear, if Cubist decides to buy remaining untendered shares.



👍️0

Your Recent History

Delayed Upgrade Clock